Medikaloka Hermina Valuation
| HEAL Stock | IDR 1,505 5.00 0.33% |
At this time, the firm appears to be overvalued. Medikaloka Hermina secures a last-minute Real Value of 1233.75 per share. The latest price of the firm is 1505.0. Our model forecasts the value of Medikaloka Hermina from analyzing the firm fundamentals such as Current Valuation of 23.44 T, profit margin of 0.1 %, and Return On Equity of 0.14 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Medikaloka Hermina's price fluctuation is very steady at this time. Calculation of the real value of Medikaloka Hermina is based on 3 months time horizon. Increasing Medikaloka Hermina's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Medikaloka Hermina's intrinsic value may or may not be the same as its current market price of 1,505, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1505.0 | Real 1233.75 | Hype 1505.0 | Naive 1589.82 |
The intrinsic value of Medikaloka Hermina's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Medikaloka Hermina's stock price.
Estimating the potential upside or downside of Medikaloka Hermina PT helps investors to forecast how Medikaloka stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Medikaloka Hermina more accurately as focusing exclusively on Medikaloka Hermina's fundamentals will not take into account other important factors: Medikaloka Hermina Total Value Analysis
Medikaloka Hermina PT is currently forecasted to have takeover price of 23.44 T with market capitalization of 22.15 T, debt of 1.47 T, and cash on hands of 590.19 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Medikaloka Hermina fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
23.44 T | 22.15 T | 1.47 T | 590.19 B |
Medikaloka Hermina Investor Information
About 51.0% of the company shares are held by company insiders. The company recorded earning per share (EPS) of 32.62. Medikaloka Hermina last dividend was issued on the 7th of June 2022. The entity had 5:1 split on the 30th of July 2021. Based on the key measurements obtained from Medikaloka Hermina's financial statements, Medikaloka Hermina PT is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Medikaloka Hermina Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Medikaloka Hermina has an asset utilization ratio of 76.72 percent. This suggests that the Company is making 0.77 for each dollar of assets. An increasing asset utilization means that Medikaloka Hermina PT is more efficient with each dollar of assets it utilizes for everyday operations.Medikaloka Hermina Ownership Allocation
Medikaloka Hermina maintains a total of 14.48 Billion outstanding shares. Medikaloka Hermina PT holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Medikaloka Hermina Profitability Analysis
The company reported the revenue of 5.82 T. Net Income was 1 T with profit before overhead, payroll, taxes, and interest of 2.71 T.About Medikaloka Hermina Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Medikaloka Hermina PT. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Medikaloka Hermina based exclusively on its fundamental and basic technical indicators. By analyzing Medikaloka Hermina's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Medikaloka Hermina's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Medikaloka Hermina. We calculate exposure to Medikaloka Hermina's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Medikaloka Hermina's related companies.PT Medikaloka Hermina Tbk operates a network of general hospitals in Indonesia. The company was founded in 1999 and is based in Jakarta, Indonesia. Medikaloka Hermina operates under Medical Care Facilities classification in Indonesia and is traded on Jakarta Stock Exchange. It employs 10547 people.
8 Steps to conduct Medikaloka Hermina's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Medikaloka Hermina's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Medikaloka Hermina's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Medikaloka Hermina's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Medikaloka Hermina's revenue streams: Identify Medikaloka Hermina's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Medikaloka Hermina's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Medikaloka Hermina's growth potential: Evaluate Medikaloka Hermina's management, business model, and growth potential.
- Determine Medikaloka Hermina's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Medikaloka Hermina's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Other Information on Investing in Medikaloka Stock
Medikaloka Hermina financial ratios help investors to determine whether Medikaloka Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medikaloka with respect to the benefits of owning Medikaloka Hermina security.